Amcad Biomed (ROCO:4188) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
50 GF Score
Price NT$16.15
GF Value NT$9.65
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Amcad Biomed Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:4188
50GF Score
Amcad Biomed Corp ROCO:4188
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$16.15 is trading 67.4% above its estimated GF Value™ of NT$9.65. GuruFocus considers Amcad Biomed to be Significantly Overvalued.

Key valuation signals for ROCO:4188:

  • Dividends Received:
  • GF Value™: NT$9.65 vs. price of NT$16.15 (67.4% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
50GF Score

Get the complete analysis for ROCO:4188

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.15
Price
NT$9.65
GF Value